<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab3_21">
 <label>Table 21.3</label>
 <caption>
  <p>Antiviral treatments for common viral pneumonia</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th/>
    <th>Oseltamivir</th>
    <th>Zanamivir</th>
    <th>Ribavirin</th>
    <th>Cidofovir</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Therapeutic class</td>
    <td>Neuraminidase inhibitor</td>
    <td>Neuraminidase inhibitor</td>
    <td>Nucleoside analogue</td>
    <td>Nucleoside analogue</td>
   </tr>
   <tr>
    <td>Route</td>
    <td>Oral</td>
    <td>Inhaled</td>
    <td>Inhaled</td>
    <td>Intravenous</td>
   </tr>
   <tr>
    <td>Regimen</td>
    <td>75 mg 
     <italic>bid</italic>
    </td>
    <td>10 mg 
     <italic>bid</italic>
    </td>
    <td>Up to 2 g 
     <italic>tid</italic>
     <sup>a</sup>
    </td>
    <td>5 mg/kg weekly
     <sup>a</sup>
    </td>
   </tr>
   <tr>
    <td>Duration</td>
    <td>5 days</td>
    <td>5 days</td>
    <td>10 days
     <sup>a</sup>
    </td>
    <td>Variable
     <sup>b</sup>
    </td>
   </tr>
   <tr>
    <td>Side effects</td>
    <td>Rash</td>
    <td>Rash bronchospasm</td>
    <td>Haemolytic anaemia
     <sup>d</sup> bronchospasm
    </td>
    <td>Nephrotoxicity
     <sup>
      <bold>c</bold>
     </sup> myelosuppression retinitis
    </td>
   </tr>
   <tr>
    <td>Indication</td>
    <td>Influenza</td>
    <td>Influenza</td>
    <td>RSV
     <sup>e</sup>
    </td>
    <td>Adenovirus
     <sup>e</sup>
    </td>
   </tr>
   <tr>
    <td>Evidence supporting use</td>
    <td>Cohort studies</td>
    <td>Cohort studies</td>
    <td>Cohort studies</td>
    <td>Cohort studies</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>NA</italic> not available, 
   <italic>bid</italic> twice daily, 
   <italic>tid</italic> three times daily
  </p>
  <p>
   <sup>a</sup>The therapeutic regimens are those described in the available literature
  </p>
  <p>
   <sup>b</sup>Cidofovir is given in a dose of 5 mg/kg weekly for 2 weeks then every 2 weeks according to the clinical response
  </p>
  <p>
   <sup>
    <bold>c</bold>
   </sup>Hyperhydratation and probenecide may help to prevent cidofovir nephrotoxicity
  </p>
  <p>
   <sup>d</sup>Haemolytic anaemia may be readily controlled by blood transfusion
  </p>
  <p>
   <sup>e</sup>These drugs have not been approved by regulating authorities in these indications
  </p>
 </table-wrap-foot>
</table-wrap>
